T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials. To guide precision immunotherapy, other factors should also be taken into consideration, including greater availability of immune targets and compounds with different modes of action during the development of new biomarkers, and determinants of response and resistance to a specific regimen.
In this technical session, Creative Biolabs invited Dr. Bruno Paiva to give us a clearer understanding of novel immunotherapies and the combined methods to be applied in the research of tumorigenesis and drug development.
Dr. Bruno Paiva, PharmD, Ph.D., is a research fellow of the Departments of Haematology and Immunology at the Clinica Universidad de Navarra and CIMA, Pamplona, Spain. He is also the Director of the Flow Cytometry Core of the University of Navarra.
Dr. Paiva's main area of expertise is the multidimensional flow cytometry analysis of hematological malignancies. His research focuses on immunogenomics to improve differential diagnosis, risk stratification, and monitoring of patients with monoclonal gammopathies and myeloid malignancies. He is an author or co-author of hundreds of publications in peer-reviewed journals, and has been recognized with numerous awards.